Adverse effects of antiretroviral therapy

Focus on bone density

Alessandra Viganò, Stefano Mora

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Osteopenia and osteoporosis are the most important bone disorders affecting patients with HIV infection. The available data indicate that HIV-infected patients have a high prevalence of low bone mineral density. Reduced bone mass and alterations of bone metabolism have been found in HIV-infected children, adolescents and adults. The variety and complexity of changes in bone metabolism in patients with HIV infection and the different possible mechanisms triggering bone mineral loss, as well as the different stages of disease and cumulative exposure to antiretroviral drugs at the time of clinical evaluation, may contribute to the wide range of mineral loss observed and to the uncertainty of the role of specific antiretroviral medications. 2004

Original languageEnglish
Pages (from-to)199-208
Number of pages10
JournalExpert Opinion on Drug Safety
Volume3
Issue number3
DOIs
Publication statusPublished - May 2004

Fingerprint

Bone Density
Bone and Bones
HIV Infections
Minerals
HIV
Therapeutics
Metabolic Bone Diseases
Osteoporosis
Uncertainty
Pharmaceutical Preparations

Keywords

  • Bone mass
  • Bone metabolism
  • HIV-infected adults
  • HIV-infected children

ASJC Scopus subject areas

  • Pharmacology

Cite this

Adverse effects of antiretroviral therapy : Focus on bone density. / Viganò, Alessandra; Mora, Stefano.

In: Expert Opinion on Drug Safety, Vol. 3, No. 3, 05.2004, p. 199-208.

Research output: Contribution to journalArticle

@article{0469bab279d54f0cb23987af1063a3e3,
title = "Adverse effects of antiretroviral therapy: Focus on bone density",
abstract = "Osteopenia and osteoporosis are the most important bone disorders affecting patients with HIV infection. The available data indicate that HIV-infected patients have a high prevalence of low bone mineral density. Reduced bone mass and alterations of bone metabolism have been found in HIV-infected children, adolescents and adults. The variety and complexity of changes in bone metabolism in patients with HIV infection and the different possible mechanisms triggering bone mineral loss, as well as the different stages of disease and cumulative exposure to antiretroviral drugs at the time of clinical evaluation, may contribute to the wide range of mineral loss observed and to the uncertainty of the role of specific antiretroviral medications. 2004",
keywords = "Bone mass, Bone metabolism, HIV-infected adults, HIV-infected children",
author = "Alessandra Vigan{\`o} and Stefano Mora",
year = "2004",
month = "5",
doi = "10.1517/eods.3.3.199.31072",
language = "English",
volume = "3",
pages = "199--208",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Adverse effects of antiretroviral therapy

T2 - Focus on bone density

AU - Viganò, Alessandra

AU - Mora, Stefano

PY - 2004/5

Y1 - 2004/5

N2 - Osteopenia and osteoporosis are the most important bone disorders affecting patients with HIV infection. The available data indicate that HIV-infected patients have a high prevalence of low bone mineral density. Reduced bone mass and alterations of bone metabolism have been found in HIV-infected children, adolescents and adults. The variety and complexity of changes in bone metabolism in patients with HIV infection and the different possible mechanisms triggering bone mineral loss, as well as the different stages of disease and cumulative exposure to antiretroviral drugs at the time of clinical evaluation, may contribute to the wide range of mineral loss observed and to the uncertainty of the role of specific antiretroviral medications. 2004

AB - Osteopenia and osteoporosis are the most important bone disorders affecting patients with HIV infection. The available data indicate that HIV-infected patients have a high prevalence of low bone mineral density. Reduced bone mass and alterations of bone metabolism have been found in HIV-infected children, adolescents and adults. The variety and complexity of changes in bone metabolism in patients with HIV infection and the different possible mechanisms triggering bone mineral loss, as well as the different stages of disease and cumulative exposure to antiretroviral drugs at the time of clinical evaluation, may contribute to the wide range of mineral loss observed and to the uncertainty of the role of specific antiretroviral medications. 2004

KW - Bone mass

KW - Bone metabolism

KW - HIV-infected adults

KW - HIV-infected children

UR - http://www.scopus.com/inward/record.url?scp=2942635267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942635267&partnerID=8YFLogxK

U2 - 10.1517/eods.3.3.199.31072

DO - 10.1517/eods.3.3.199.31072

M3 - Article

VL - 3

SP - 199

EP - 208

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -